The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions

•CYP11A1 initiates a novel pathway of vitamin D metabolism.•The novel seocosteroidogenic pathway can operate in tissues expressing CYP11A1.•5,7-Dienes generated by CYP11A1 or their products serve as precursors for novel secosteroids.•CYP11A1-derived secosteroids with a short or full-length side chai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of steroid biochemistry and molecular biology 2014-10, Vol.144, p.28-39
Hauptverfasser: Slominski, Andrzej T., Kim, Tae-Kang, Li, Wei, Yi, Ae-Kyung, Postlethwaite, Arnold, Tuckey, Robert C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•CYP11A1 initiates a novel pathway of vitamin D metabolism.•The novel seocosteroidogenic pathway can operate in tissues expressing CYP11A1.•5,7-Dienes generated by CYP11A1 or their products serve as precursors for novel secosteroids.•CYP11A1-derived secosteroids with a short or full-length side chain have desirable phenotypic activities.•Novel secosteroids are non-toxic and non-calcemic. Research over the last decade has revealed that CYP11A1 can hydroxylate the side chain of vitamin D3 at carbons 17, 20, 22 and 23 to produce at least 10 metabolites, with 20(OH)D3, 20,23(OH)2D3, 20,22(OH)2D3, 17,20(OH)2D3 and 17,20,23(OH)3D3 being the main products. However, CYP11A1 does not act on 25(OH)D3. The placenta, adrenal glands and epidermal keratinocytes have been shown to metabolize vitamin D3 via this CYP11A1-mediated pathway that is modified by the activity of CYP27B1, with 20(OH)D3 (the major metabolite), 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3 and 17,20,23(OH)3D3 being detected, defining these secosteroids as endogenous regulators/natural products. This is supported by the detection of a mono-hydroxyvitamin D3 with the retention time of 20(OH)D3 in human serum. In new work presented here we demonstrate that the CYP11A1-initiated pathways also occurs in Caco-2 colon cells. Our previous studies show that 20(OH)D3 and 20,23(OH)2D3 are non-calcemic at pharmacological doses, dependent in part on their lack of a C1α hydroxyl group. In epidermal keratinocytes, 20(OH)D3, 20(OH)D2 and 20,23(OH)2D3 inhibited cell proliferation, stimulated differentiation and inhibited NF-κB activity with potencies comparable to 1,25(OH)2D3, acting as partial agonists on the VDR. 22(OH)D3 and 20,22(OH)2D3, as well as secosteroids with a short or no side chain, showed antiproliferative and prodifferentiation effects, however, with lower potency than 20(OH)D3 and 20,23(OH)2D3. The CYP11A1-derived secosteroids also inhibited melanocyte proliferation while having no effect on melanogenesis, and showed anti-melanoma activities in terms of inhibiting proliferation and the ability to grow in soft agar. Furthermore, 20(OH)D3 and 20,23(OH)2D3 showed anti-fibrosing effects in vitro, and also in vivo for the former. New data presented here shows that 20(OH)D3 inhibits LPS-induced production of TNFα in the J774 line, TNFα and IL-6 in peritoneal macrophages and suppresses the production of proinflammatory Th1/Th17-related cytokines, while promoting the production of the anti-inflammatory cytokine
ISSN:0960-0760
1879-1220
DOI:10.1016/j.jsbmb.2013.10.012